Cross-over, open-label trial of the effects of gabapentin versus pregabalin on painful peripheral neuropathy and health-related quality of life in haemodialysis patients

Clinical Drug Investigation

Volumn 33, Issue 6, 2013, Pages 401-408

  Atalay, Huseyin ^a   Solak, Yalcin ^a,b   Biyik, Zeynep ^a   Gaipov, Abduzhappar ^a   Guney, Figen ^a   Turk, Suleyman ^a  

^a SELCUK UNIVERSITY   (Turkey)

^b Karaman Devlet Hastanesi   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN; PREGABALIN;

ADULT; ARTICLE; BALANCE DISORDER; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; ELECTROMYOGRAPHY; EUPHORIA; FEMALE; HEMODIALYSIS PATIENT; HUMAN; INSOMNIA; MALE; MCGILL PAIN QUESTIONNAIRE; MYOCLONUS; NAUSEA; NEUROPATHIC PAIN; OPEN STUDY; OUTCOME ASSESSMENT; PAIN; PAINFUL PERIPHERAL NEUROPATHY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; TREMOR; XEROSTOMIA;

ADULT; AGED; AMINES; ANALGESICS; CROSS-OVER STUDIES; CYCLOHEXANECARBOXYLIC ACIDS; FEMALE; FOLLOW-UP STUDIES; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PERIPHERAL NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 84878676726     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0080-2     Document Type: Article

References (32)

1. Krishnan AV, Phoon RK, Pussell BA, Charlesworth JA, Bostock H, Kiernan MC. Altered motor nerve excitability in end-stage kidney disease. Brain. 2005;128(Pt 9):2164-74.
2. Krishnan AV, Kiernan MC. Uremic neuropathy: clinical features and new pathophysiological insights. Muscle Nerve. 2007;35(3):273-90.
3. Bazzi C, Pagani C, Sorgato G, Albonico G, Fellin G, D'Amico G. Uremic polyneuropathy: a clinical and electrophysiological study in 135 short- and long-term hemodialyzed patients. Clin Nephrol. 1991;35(4):176-81.
4. Krishnan AV, Kiernan MC. Neurological complications of chronic kidney disease. Nat Rev Neurol. 2009;5(10):542-51.
5. Davison SN. Pain in hemodialysis patients: prevalence, cause, severity, and management. Am J Kidney Dis. 2003;42(6):1239-47.
6. Currie CJ, Poole CD, Woehl A, Morgan CL, Cawley S, Rousculp MD, et al. The health-related utility and health-related quality of life of hospital-treated subjects with type 1 or type 2 diabetes with particular reference to differing severity of peripheral neuropathy. Diabetologia. 2006;49(10):2272-80.
7. Yoshida S, Hirai M, Suzuki S, Awata S, Oka Y. Neuropathy is associated with depression independently of health-related quality of life in Japanese patients with diabetes. Psychiatry Clin Neurosci. 2009;63(1):65-72.
8. Mapes DL, Lopes AA, Satayathum S, McCullough KP, Goodkin DA, Locatelli F, et al. Health-related quality of life as a predictor of mortality and hospitalization: the dialysis outcomes and practice patterns study (DOPPS). Kidney Int. 2003;64(1):339-49.
9. Hupperts RM, Leunissen KM, van Hooff JP, Lodder J. Recovery of uremic neuropathy after renal transplantation. Clin Neurol Neurosurg. 1990;92(1):87-9.
10. Ho DT, Rodig NM, Kim HB, Lidov HG, Shapiro FD, Raju GP, et al. Rapid reversal of uremic neuropathy following renal transplantation in an adolescent. Pediatr Transplant. 2011;16(7):E296-300.
11. Attal N, Cruccu G, Haanpaa M, Hansson P, Jensen TS, Nurmikko T, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006;13(11):1153-69.
12. Melzack R. The short-form McGill pain questionnaire. Pain. 1987;30(2):191-7.
13. Kuǧuoǧlu SE-AF, Olgun N. McGill Melzack aǧrI soru formunun Türkçe'ye uyarlanmasI. AǧrI. 2003;15:47-51.
14. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473-83.
15. Koçyiǧit HAÖ, Ölmez N. SF-36'nιn Türkçe için güvenilirliǧi ve geç erliliǧi. Ege Fizik Tedavi ve Rehabilitasyon Dergisi. 1999.
16. Ware JE Jr, Kosinski M, Bayliss, McHorney CA, Rogers WH, Raczek A. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the medical outcomes study. Med Care. 1995;33(4 Suppl):AS264-79.
17. Johansen KL, Painter P, Kent-Braun JA, Ng AV, Carey S, Da Silva M, et al. Validation of questionnaires to estimate physical activity and functioning in end-stage renal disease. Kidney Int. 2001;59(3):1121-7.
18. Oh SJ. Anatomical guide for common nerve conduction studies. In: Oh SJ, editor. Clinical electromyography: nerve conduction studies. 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 2003. p. 202-75.
19. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2011;3:CD007938.
20. Anastassiou E, Iatrou CA, Vlaikidis N, Vafiadou M, Stamatiou G, Plesia E, et al. Impact of pregabalin treatment on pain, pain-related sleep interference and general well-being in patients with neuropathic pain: a non-interventional, multicentre, post-marketing study. Clin Drug Investig. 2011;31(6):417-26.
21. Olesen SS, Graversen C, Olesen AE, Frokjaer JB, Wilder-Smith O, van Goor H, et al. Randomised clinical trial: pregabalin attenuates experimental visceral pain through sub-cortical mechanisms in patients with painful chronic pancreatitis. Aliment Pharmacol Ther. 2011;34(8):878-87.
22. Argoff CE. The coexistence of neuropathic pain, sleep, and psychiatric disorders: a novel treatment approach. Clin J Pain. 2007;23(1):15-22.
23. Bazil CW, Dave J, Cole J, Stalvey J, Drake E. Pregabalin increases slow-wave sleep and may improve attention in patients with partial epilepsy and insomnia. Epilepsy Behav. 2012;23(4):422-5.
24. Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005;62(9):1022-30.
25. Delahoy P, Thompson S, Marschner IC. Pregabalin versus gabapentin in partial epilepsy: a meta-analysis of dose-response relationships. BMC Neurol. 2010;10:104.
26. Toth C. Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy. Pain Med. 2010;11(3):456-65.
27. Tzellos TG, Papazisis G, Toulis KA, Sardeli C, Kouvelas D. A2delta ligands gabapentin and pregabalin: future implications in daily clinical practice. Hippokratia. 2010;14(2):71-5.
28. Gilron I, Wajsbrot D, Therrien F, Lemay J. Pregabalin for peripheral neuropathic pain: a multicenter, enriched enrollment randomized withdrawal placebo-controlled trial. Clin J Pain. 2011;27(3):185-93.
29. Satoh J, Yagihashi S, Baba M, Suzuki M, Arakawa A, Yoshiyama T, et al. Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial. Diabet Med. 2011;28(1):109-16.
30. Perez C, Navarro A, Saldana MT, Masramon X, Rejas J. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study. Clin Ther. 2010;32(7):1357-70.
31. Turkmen K, Yazici R, Solak Y, Guney I, Altintepe L, Yeksan M, et al. Health-related quality of life, sleep quality, and depression in peritoneal dialysis and hemodialysis patients. Hemodial Int. 2012;16(2):198-206.
32. Davison SN, Jhangri GS. Impact of pain and symptom burden on the health-related quality of life of hemodialysis patients. J Pain Symptom Manage. 2010;39(3):477-85.